(San Francisco) -- Mytrus, an innovative clinical technology and services company for medical and pharmaceutical research, today announced that its iPad® application explaining informed consent prior to clinical trial patient enrollment has been selected for use in a global, multi-year study supported by The National Institute of Neurological Disorders and Stroke (NINDS).
Led by researchers from the University of California, San Francisco (UCSF) Stroke Sciences Group, the five-year POINT clinical trial involves 4,150 patients in 120 clinical test sites in every region of the globe. A number of NINDS Neurological Emergencies Treatment Trials (NETT) Network clinical site hubs are participating, supplemented and supported by sites through the NETT Clinical Coordinating Center at the University of Michigan.
"We believe that a visual and interactive method of informing patients about the trial will standardize the way patients are informed and consented across any large and diverse study," said Claiborne Johnston, MD, PhD, Principal Investigator of the POINT Trial and Associate Vice Chancellor of Research at the University of California, San Francisco.
Using animation and other visual imagery, the Mytrus iPad application is the first in the industry to condense the complex and critical disclosure information required at the start of a clinical trial into an easy-to-understand, digitized format. This new approach not only helps patients better understand the clinical trial process; it helps researchers control costs through quicker study starts. It is also the perfect tool for use with a diverse population, an important consideration for protocol compliance in global studies dependent on participants with varying levels of education.
The Mytrus iPad application can easily be tailored to support any clinical trial design or protocol. For this project, Mytrus created three programs: English, Spanish and Mandarin.
"Mytrus continues to rapidly expand the use of its technology in clinical trials at home and abroad,” said Anthony Costello, CEO of Mytrus. "Our selection for use in this long-term study, spanning sites in North and South America, Asia/Pacific and Europe, continues to validate our platform as one that is easy to adopt and that provides an immediate ROI."
About the Mytrus Application
The Mytrus mobile application for tablets facilitates quick patient enrollment and enables patient supplied data to be fed directly into a clinical trial database. It helps researchers streamline the clinical trial data collection process and makes it easy to conduct a clinical trial in sites where affected populations are present – no matter how remote that location might be. Data entered at the site is quickly synced with the clinical trial database, giving researchers anywhere in the world a better methodology for monitoring potential adverse effects and patient progress.
The information stated above was prepared by Mytrus and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of Mytrus, or any of its products, by The Regents of the University of California, its officers, agents and employees.
Founded in 2009, Mytrus is a California-based clinical technology and services company which is revolutionizing traditional clinical trials with its simple, efficient, and patient-centered technologies. Creating interactive tools which improve patient comprehension and comfort, Mytrus streamlines the clinical trial process, dramatically improving patient recruitment timelines, increasing patient retention and reducing overall study costs for sponsors. At a time when bringing a drug to market can cost up to $1 billion, Mytrus provides solutions for pharmaceutical, biotech and device makers eager to find more cost effective ways to conduct research. Mytrus is partially owned by inVentiv Health, a global life science knowledge and services company innovating for the new health care environment.